From the Journals

Three symptoms suggest higher risk for self-injury in cancer


 

FROM JAMA ONCOLOGY

Self-injury vs. suicidality

Commenting on the study for this news organization, Madeline Li, MD, PhD, a psychiatrist and clinician-scientist at Toronto’s Princess Margaret Cancer Centre, said that the findings are “underwhelming” because they tell us what is already known – that “NFSI is associated with distress, and cancer is a stressor.” It would have been more interesting to ask how to distinguish patients at risk for suicide from those at risk for self-harm without suicide, she added.

“The way these authors formulated NFSI included both self-harm intent and suicidal intent,” she explained. The researchers compared patients who were at risk for these two types of events with patients without NFSI. “When we see self-harm without suicidal intent in the emergency room, it’s mostly people making cries for help,” said Dr. Li. “These are people who cut their wrists or take small overdoses on purpose without the intent to die. It would have been more interesting to see if there are different risk factors for people who are just going to self-harm vs. those who are actually going to attempt suicide.”

The study’s identification of risk factors for NSFI is important because “it does tell us that when there’s anxiety, depression, and shortness of breath, we should pay attention to these patients and do something about it,” said Dr. Li. Still, research in cancer psychiatry needs to shift its focus from identifying and addressing existing risk factors to preventing them from developing, she added.

“We need to move earlier and provide emotional and mental health support to cancer patients to prevent them from becoming suicidal, rather than intervening when somebody already is,” Dr. Li concluded.

The study was funded by the Hanna Research Award from the division of surgical oncology at the Odette Cancer Centre–Sunnybrook Health Sciences Centre and by a Sunnybrook Health Sciences Centre Alternate Funding Plan Innovation grant. It was also supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care. Dr. Hallet has received personal fees from Ipsen Biopharmaceuticals Canada and AAA outside the submitted work. Dr. Li reported no relevant financial relationships.

A version of this article first appeared on Medscape.com.

Pages

Recommended Reading

Medicaid to cover routine costs for patients in trials
MDedge ObGyn
New approach to breast screening based on breast density at 40
MDedge ObGyn
JAMA podcast on racism in medicine faces backlash
MDedge ObGyn
Genetic testing for breast and ovarian cancer: What has changed and what still needs to change?
MDedge ObGyn
JAMA editor resigns over controversial podcast
MDedge ObGyn
SNP chips deemed ‘extremely unreliable’ for identifying rare variants
MDedge ObGyn
Starting April 5, patients can read your notes: 5 things to consider
MDedge ObGyn
New guidelines on antibiotic prescribing focus on shorter courses
MDedge ObGyn
Cancer screening stopped by pandemic: Repercussions to come?
MDedge ObGyn
Pill not enough for ‘sexual problems’ female cancer patients face
MDedge ObGyn